Catalyst, Korea’s ISU ABXIS Plan Clinical Studies of Coagulation Factor for Hemophilia B

Catalyst, Korea’s ISU ABXIS Plan Clinical Studies of Coagulation Factor for Hemophilia B
0
(0)

San Francisco-based Catalyst Biosciences has completed toxicology studies of its new drug CB 2679d/ISU304 — a highly potent next-generation coagulation factor to treat hemophilia B. This  follows the therapy’s recent Investigational New Drug (IND) approval, a necessary step before starting clinical studies, by the Korean Ministry of Food and Drug Safety.

Patients with hemophilia B lack the clotting protein factor IX. This leads to severe and spontaneous bleeding episodes, as well as longer bleeding times that can become life-threatening.

“Individuals with severe hemophilia B will experience abnormal bleeding, not just after an injury, but spontaneously into potentially any organ, joints or muscles,” Nassim Usman, PhD, president and CEO of Catalyst, said in a press release. “Without preventative treatment or prophylaxis, these individuals may experience several spontaneous bleeding episodes per month.”

Standard treatment requires frequent intravenous infusions of human factor IX. However, adherence and access to peripheral veins can be difficult, often requiring the use of central venous devices that increase the risk of infection and thrombosis. Furthermore, the leading human factor IX on the market has a short half-life and is therefore not ideal for preventative treatment — leading to the need for safer, more efficient therapies.

“Our vision is to prevent bleeding with the stabilization and normalization of clotting levels using more convenient subcutaneous dosing,” Usman said.

Catalyst has been developing CB 2679d/ISU304, a factor IX variant, in collaboration with South Korea’s ISU ABXIS. This project is part of its larger goal of developing novel hematology medicines. Pre-clinical studies in animal models of hemophilia have shown that a daily subcutaneous injection of CB 2679d/ISU304 can normalize human factor IX levels.

ISU ABXIS is now in charge of advancing the factor IX program towards its first human clinical trial. In this regard, it plans to launch a Phase 1/2 study evaluating single and multiple subcutaneous injections of CB 2679d/ISU304 in people with severe hemophilia B in the next few months.

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

×

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

Latest Posts
  • polypharmacy, aging, hemophilia
  • Regeneron, Intellia
  • Hemlibra and treatment costs
  • Cyklokapron and joint surgery

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This